Immune response on outcomes in hepatocellular carcinoma

Norifumi Iseda, Shinji Itoh, Takahiro Tomiyama, Akinari Morinaga, Huanlin Wang, Tomonari Shimagaki, Takeshi Kurihara, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Tomohiro Iguchi, Tomoharu Yoshizumi, Masaki Mori

研究成果: Contribution to journalArticle査読

1 被引用数 (Scopus)

抄録

Recently, immune checkpoint inhibitors (ICI) has been developed considerably. ICI has already been approved for malignant melanoma, lung cancer and renal cancer. We expected ICI to be taken for many cancers in the future. Therefore, the development of biomarker for them are needed. The recent large phase EI study IMbrave 150 evaluated atezolizumab plus bevacizumab vs sorafenib as the first treatment for patients with unresectable hepatocellular carcinoma (HCC). IMbrave 150 demonstrated statistically significant and clinically meaningful improvements in both OS and RFS for atezolizumab plus bevacizumab compared with sorafenib in HCC patients. A paradigm shift in the treatment of unresectable HCC is about to occur. In this article, we discussed the significance and biomarkers of tumor immunity in HCC microenvironment.

本文言語英語
ページ(範囲)1303-1306
ページ数4
ジャーナルJapanese Journal of Cancer and Chemotherapy
47
9
出版ステータス出版済み - 9 2020

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Immune response on outcomes in hepatocellular carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル